L. Darjania

发表

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Journal of medicinal chemistry.

Dynamic turnover of arabinogalactan proteins in cultured Arabidopsis cells

G. A. Thompson, T. Okamoto, L. Darjania, 2002 .

Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.

Shunyou Wang, Katrina Chan, C. Rommel, 2011 .

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Molecular and Cellular Biochemistry.

Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties.

Adam Siddiqui-Jain, Nicole Streiner, Caroline B. Ho, 2011, Bioorganic & medicinal chemistry letters.

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

P. Zarrinkar, K. Yu, D. Brehmer, 2018, Cell.

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.

Adam Siddiqui-Jain, J. Bliesath, Diwata Macalino, 2012, ACS medicinal chemistry letters.

Abstract 5168: KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors

K. Yu, Tao Wu, F. Burrows, 2017 .

Effect of two cAMP analogues on stomatal opening in Vicia faba. Possible relationship with cytosolic calcium concentration

S. Delmastro, S. Delmastro, N. Curvetto, 1994 .

Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer

Shunyou Wang, Katrina Chan, C. Rommel, 2011 .

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.